• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Research, generic/biosimilar industries call for integrated strategy for Europe

Research, generic/biosimilar industries call for integrated strategy for Europe

December 18, 2014
CenterWatch Staff

Ahead of the adoption of the European Commission Work Program, the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Generic Medicines Association (EGA) have reiterated their joint Europe 2020 strategy submission for an industrial policy for the globalization era and the value it places in the pharmaceutical sector. The joint submission highlights key proposals on how to successfully integrate the pharmaceutical sector for an industrial policy that will boost European health and wealth alike.

The E.U. pharmaceutical sector can compete globally if the E.U.:

  • Adopts efficient regulatory measures through open and transparent input from healthcare stakeholders
  • Promotes stable and predictable pharmaceutical markets that support investment in innovation and that stimulate healthy and sustainable generic and biosimilar medicines competition
  • Makes Europe an attractive location for investment in research, development and manufacturing of pharmaceuticals
  • Cooperates with the industry to address new health risks and expand its manufacturing capabilities to securely provide for its own medicine needs.

Richard Bergström, director general EFPIA, said, “The Competitiveness Council recently called on the Commission to pursue sectorial initiatives, notably for high growth potential sectors. The pharmaceutical industry is one such sector and this innovative industry, if integrated correctly in European value chains, holds great potential to continue to enhance E.U. competitiveness.” 

Adrian van den Hoven, director general EGA, said, “The pharmaceutical sector is a partner for better health and for growth and jobs in Europe. We need a decisive pharmaceutical industrial strategy to boost our manufacturing capacities to serve Europe.”

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing